Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72808 record(s)

Req # A-2020-000831

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_03271551.

Organization: Health Canada

7 page(s)
January 2021

Req # A-2020-000832

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_03271550.

Organization: Health Canada

7 page(s)
January 2021

Req # A-2020-000835

Adverse Reaction Reports (AERs) for Pamidronate Disodium. Report numbers: E2B_02767440, E2B_02767451, E2B_02767852, E2B_02767858, E2B_02767922.

Organization: Health Canada

49 page(s)
January 2021

Req # A-2020-000849

Adverse Reaction Reports (AERs). Report numbers: E2B_03172472, E2B_03173344, E2B_03173431, E2B_03175561.

Organization: Health Canada

89 page(s)
January 2021

Req # A-2020-000851

Adverse Reaction Reports (AERs). Report numbers: E2B_03199841, E2B_03206799, E2B_03207460, E2B_03222251.

Organization: Health Canada

47 page(s)
January 2021

Req # A-2020-000856

Adverse Reaction Reports (AERs). Report numbers: E2B_03207491; E2B_03209790; E2B_03212224; E2B_03212536.

Organization: Health Canada

100 page(s)
January 2021

Req # A-2020-000857

Adverse Reaction Reports (AERs). Report numbers: E2B_02836616, E2B_02864251, E2B_02854101, 000911607, E2B_03042781, E2B_03045681, E2B_03051219, 000908424, E2B_03063606, E2B_03125521.

Organization: Health Canada

93 page(s)
January 2021

Req # A-2020-000868

Adverse Reaction Report (AER) for C1 Esterase Inhibitor (Human). Report number: E2B_03184173. ADRs for GAMMAGARD LIQUID: 000914469, E2B_03202144. ADRs for Mesalazine: E2B_03203957, E2B_03208437. ADRs for VYVANSE: E2B_03174445, E2B_03175996,…

Organization: Health Canada

116 page(s)
January 2021

Req # A-2020-000877

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-106968-891.

Organization: Health Canada

12 page(s)
January 2021

Req # A-2020-000895

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108363-178, Shared Services Partnership.

Organization: Health Canada

106 page(s)
January 2021
Date modified: